NKTR Revenue And EPS Below Consensus But "Neither Truly Matter At This Point," Says Brean Murray

Nektar Therapeutics NKTR reported 1Q11 revenue of $11.3 million and EPS of $(0.33), “both of which are below consensus of $17.2 and $(0.27), but neither truly matter at this point in Nektar's development,” Brean Murray reports. Nektar Therapeutics closed Wednesday at $9.96.